An Examination of the Nitric OxideBased Drug Market Which is Worth $20.6 Billion in 2005 and is Predicted to Grow to $52 Billion by 2015



Research and Markets (http://www.researchandmarkets.com/reports/c9692 ) has announced the addition of the Jain PharmaBiotech report: Nitric Oxide - Therapeutics, Markets and Companies to their offering.

In the worldwide pharmaceutical market, share of drugs where NO is involved in the mechanism of action is $20.6 billion in 2005 and is projected to rise to $34.1 billion in 2010 and $52 billion in 2015 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.

This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.

Nitric oxide (NO) can generate free radicals as well as scavenge them. It also functions as a signaling molecule and has an important role in the pathogenesis of several diseases. A major focus is delivery of NO by various technologies. Another approach is modulation of nitric oxide synthase (NOS), which converts L-arginine to NO. NOS can be stimulated as well as inhibited by pharmacological and gene therapy approaches.

Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. The first therapeutic use of NO was by inhaltion for acute respiratory distress syndrome (ARDS). NO-donors, NO-mimics and NOS modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified.

Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described. The text is supplemented with 25 tables and 19 figures.

The number of companies that have a product or products involving NO and free radicals is quite large and difficult to determine precisely as this is not the main focus of these companies. The report includes profiles of 38 companies involved in this area of which 9 are exclusively devoted to NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important collaborations in this area are tabulated.

There are over 80,000 publications relevant to NO. Selected 400 references are included in bibliography. It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.

Topics Covered:
Executive Summary
1 Introduction
2 Nitric Oxide Pathways
3 Role of NO in Physiology
4 Role of NO in Diseases
5 Pharmacology
6 Therapeutic Applications
7 Evaluation of NO-Based Drugs
8 Markets for NO-based Therapies
9 Companies
10 References

For more information visit http://www.researchandmarkets.com/reports/c9692

Laura Wood
Senior Manager
Research and Markets
Fax : +353 1 4100 980





An Examination of the Nitric OxideBased Drug Market Which is Worth $20.6 Billion in 2005 and is Predicted to Grow to $52 Billion by 2015